Telaprevir News and Research

RSS
Studies demonstrate encouraging results for new direct-acting antiviral agents

Studies demonstrate encouraging results for new direct-acting antiviral agents

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

Abstracts on Bristol-Myers Squibb's research in liver disease accepted for presentation

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

SCYNEXIS announces results from SCY-635 Phase 2a study on HCV

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

Telaprevir offers advantages in patients with chronic hepatitis C infection of genotype 1

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Vitamin B12 supplements and hepatitis C treatment: an interview with Gerardo Nardone and Alba Rocco

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

New research reveals effective treatments for gastrointestinal conditions

New research reveals effective treatments for gastrointestinal conditions

New data provides hope for HCV non-responders

New data provides hope for HCV non-responders

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

Bristol-Myers Squibb, Janssen expand TMC435, BMS-986094 clinical collaboration agreement

DDW to be held May 19-22 in San Diego

DDW to be held May 19-22 in San Diego

Medivir initiates two new HPC3001 and HPC3011 phase III trials in HCV

Medivir initiates two new HPC3001 and HPC3011 phase III trials in HCV

Routine hepatitis C testing of the middle aged could save thousands of lives: CDC report

Routine hepatitis C testing of the middle aged could save thousands of lives: CDC report

New triple-therapies found cost-effective for chronic hepatitis C patients with advanced liver disease

New triple-therapies found cost-effective for chronic hepatitis C patients with advanced liver disease

New combo drug helps suppress hepatitis C genotype 1 infection

New combo drug helps suppress hepatitis C genotype 1 infection

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Vertex announces positive interim data from INCIVEK Phase 2 combination trial on HIV, HCV

Studies on effectiveness of new HCV therapies presented at 76th ACG meeting

Studies on effectiveness of new HCV therapies presented at 76th ACG meeting

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C